<DOC>
	<DOCNO>NCT01486251</DOCNO>
	<brief_summary>The purpose study evaluate quantify dynamic modification tumor blood perfusion axitinib therapy patient refractory mCRC dose Axitinib .</brief_summary>
	<brief_title>Assessment Tumor Vascular Effects Axitinib With Dynamic Ultrasonography Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Patients histologically confirm diagnosis CRC Measurable metastatic disease liver proven disease progression ( accord RECIST criterion ) baseline ( within 4 week prior study entry ) , least one lesion &gt; 2cm consider appropriate DCEUS examination Previously expose least , irinotecan , oxaliplatin fluoropyrimidine , 3 administer optimal dos , one two chemotherapy ( CT ) line metastatic disease clear resistance drug . Previous exposure bevacizumab and/or antiEGFR monoclonal antibody allow . Age ≥18 year ; Performance Status ( PS ) 02 life expectancy &gt; 3 month . Adequate biological function : Neutrophils ≥ 1.5 x 109/L ; Platelets ≥ 100 x 109/L ; Hemoglobin &gt; 9 g/dl ; Creatinine clearance &gt; 30 ml/min ( cockcroft &amp; Gault formula ) . Serum bilirubin &lt; 1,5 x upper normal limit ( UNL ) AST/ALT &lt; 5 x UNL . Signed write informed consent Female patient childbearing potential ( &lt; 2 year last menstruation ) male must use effective mean contraception study treatment least 6 month last study drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>